Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × OTHER × lorlatinib × Clear all

Phase

Status

Recruiting 9 Not yet recruiting 6 Unknown 4 Completed 4 Active not recruiting 4 Withdrawn 1 Terminated 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 88 pembrolizumab 86 Cyclophosphamide 83 Gemcitabine 68 Cisplatin 67 Magnetic Resonance Spectroscopy 65 Carboplatin 59 Radiosurgery 55 Paclitaxel 55 Nivolumab 47 Dexamethasone 45 Biopsy 41 Bevacizumab 41 Fluorouracil 38 durvalumab 37 Docetaxel 36 Surveys and Questionnaires 35 Doxorubicin 35 fludarabine 33 Rituximab 32 Oxaliplatin 32 Capecitabine 32 fludarabine phosphate 31 Radiation 31 Leucovorin 30 Melphalan 29 Cytarabine 29 Pemetrexed 27 Irinotecan 26 Etoposide 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948462 2023-12-13

NSCLC

SCRI Development Innovations, LLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡